The Cancer Letter

Inside information on cancer research and drug development

In Brief

Stand Up to Cancer and Boston College publish nursing training modules in immunotherapy

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

STAND UP TO CANCER published a series of Certification for Nursing Education training modules, with the Boston College William F. Connell School of Nursing, focused on immunotherapy.

The first web-based CNE modules will be available in July. In its first round, the program will seek to train 25 nurses working in immunotherapy. The program was announced as part of National Nurses Week, May 6-12.

The program will address providing care for cancer patients receiving immunotherapy, including education on immunology and related pathophysiology, symptom management, and nursing interventions to reduce symptom distress and promote wellness. The modules will meet CNE standards and each module will provide 3.5 to 5 contact hours from the Boston College William F. Connell School of Nursing.

Table of Contents

YOU MAY BE INTERESTED IN

Black History MonthConversation with The Cancer Letter

Shearwood McClelland III: “When you stand for something, you’re always going to be attacked.”

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

By Jacquelyn Cobb
Guest Editorial

Biomarker-driven innovation: What the FDA’s evolving strategy means for oncology

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

By Harpreet Singh
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account